Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis

Giampiero Girolomoni, Gianfranco Altomare, Fabio Ayala, Enzo Berardesca, Piergiacomo Calzavara-Pinton, Sergio Chimenti, Andrea Peserico, Antonio Puglisi Guerra, Gino Antonio Vena

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Context: The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several randomized controlled studies and meta-analyses. However, some concerns on the long-term safety of these drugs still exist, as these studies generally included small patient numbers and were performed in selected patient populations. Objective: This review presents and discusses current evidence on the safety of anti-TNFα agents in patients with psoriasis and PsA, with a focus on European registry studies and case reports of particular importance. Methods: Key studies on the safety of anti-TNFα agents in the treatment of adult patients with psoriasis or PsA were identified by a MEDLINE search (last updated 10 November 2011) based on several interrelated queries, with a focus on European registries. Other studies and case reports were included if deemed relevant. Studies concerning other conditions, such as rheumatoid arthritis (RA), were included as appropriate when data in psoriatic disease were unavailable or insufficient. Results: Available data on the safety of anti-TNFα agents such as etanercept in psoriasis and PsA appear reassuring, even if some concerns still exist. Most notably, data suggest a higher incidence of infection and lymphoma amongst patients treated with the anti-TNFα monoclonal antibodies infliximab and adalimumab compared with etanercept. Conclusion: The overall safety profile of monoclonal antibodies in patients with psoriasis, PsA and RA seems less favorable than that of etanercept, particularly in terms of risk of infection and hepatotoxicity.

Original languageEnglish
Pages (from-to)548-560
Number of pages13
JournalImmunopharmacology and Immunotoxicology
Volume34
Issue number4
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Psoriatic Arthritis
Psoriasis
Tumor Necrosis Factor-alpha
Safety
Registries
Rheumatoid Arthritis
Therapeutics
Monoclonal Antibodies
Proxy
Infection
MEDLINE
Meta-Analysis
Lymphoma
Incidence
Pharmaceutical Preparations
Population
Etanercept

Keywords

  • Adalimumab
  • Biological drugs
  • Etanercept
  • Golimumab
  • Infliximab
  • Psoriasis
  • Psoriatic arthritis
  • Registry
  • safety

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology

Cite this

Girolomoni, G., Altomare, G., Ayala, F., Berardesca, E., Calzavara-Pinton, P., Chimenti, S., ... Vena, G. A. (2012). Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacology and Immunotoxicology, 34(4), 548-560. https://doi.org/10.3109/08923973.2011.653646

Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. / Girolomoni, Giampiero; Altomare, Gianfranco; Ayala, Fabio; Berardesca, Enzo; Calzavara-Pinton, Piergiacomo; Chimenti, Sergio; Peserico, Andrea; Puglisi Guerra, Antonio; Vena, Gino Antonio.

In: Immunopharmacology and Immunotoxicology, Vol. 34, No. 4, 08.2012, p. 548-560.

Research output: Contribution to journalArticle

Girolomoni, G, Altomare, G, Ayala, F, Berardesca, E, Calzavara-Pinton, P, Chimenti, S, Peserico, A, Puglisi Guerra, A & Vena, GA 2012, 'Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis', Immunopharmacology and Immunotoxicology, vol. 34, no. 4, pp. 548-560. https://doi.org/10.3109/08923973.2011.653646
Girolomoni, Giampiero ; Altomare, Gianfranco ; Ayala, Fabio ; Berardesca, Enzo ; Calzavara-Pinton, Piergiacomo ; Chimenti, Sergio ; Peserico, Andrea ; Puglisi Guerra, Antonio ; Vena, Gino Antonio. / Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis. In: Immunopharmacology and Immunotoxicology. 2012 ; Vol. 34, No. 4. pp. 548-560.
@article{bbe5ee2f29354409bfe13bdad3d151af,
title = "Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis",
abstract = "Context: The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several randomized controlled studies and meta-analyses. However, some concerns on the long-term safety of these drugs still exist, as these studies generally included small patient numbers and were performed in selected patient populations. Objective: This review presents and discusses current evidence on the safety of anti-TNFα agents in patients with psoriasis and PsA, with a focus on European registry studies and case reports of particular importance. Methods: Key studies on the safety of anti-TNFα agents in the treatment of adult patients with psoriasis or PsA were identified by a MEDLINE search (last updated 10 November 2011) based on several interrelated queries, with a focus on European registries. Other studies and case reports were included if deemed relevant. Studies concerning other conditions, such as rheumatoid arthritis (RA), were included as appropriate when data in psoriatic disease were unavailable or insufficient. Results: Available data on the safety of anti-TNFα agents such as etanercept in psoriasis and PsA appear reassuring, even if some concerns still exist. Most notably, data suggest a higher incidence of infection and lymphoma amongst patients treated with the anti-TNFα monoclonal antibodies infliximab and adalimumab compared with etanercept. Conclusion: The overall safety profile of monoclonal antibodies in patients with psoriasis, PsA and RA seems less favorable than that of etanercept, particularly in terms of risk of infection and hepatotoxicity.",
keywords = "Adalimumab, Biological drugs, Etanercept, Golimumab, Infliximab, Psoriasis, Psoriatic arthritis, Registry, safety",
author = "Giampiero Girolomoni and Gianfranco Altomare and Fabio Ayala and Enzo Berardesca and Piergiacomo Calzavara-Pinton and Sergio Chimenti and Andrea Peserico and {Puglisi Guerra}, Antonio and Vena, {Gino Antonio}",
year = "2012",
month = "8",
doi = "10.3109/08923973.2011.653646",
language = "English",
volume = "34",
pages = "548--560",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis

AU - Girolomoni, Giampiero

AU - Altomare, Gianfranco

AU - Ayala, Fabio

AU - Berardesca, Enzo

AU - Calzavara-Pinton, Piergiacomo

AU - Chimenti, Sergio

AU - Peserico, Andrea

AU - Puglisi Guerra, Antonio

AU - Vena, Gino Antonio

PY - 2012/8

Y1 - 2012/8

N2 - Context: The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several randomized controlled studies and meta-analyses. However, some concerns on the long-term safety of these drugs still exist, as these studies generally included small patient numbers and were performed in selected patient populations. Objective: This review presents and discusses current evidence on the safety of anti-TNFα agents in patients with psoriasis and PsA, with a focus on European registry studies and case reports of particular importance. Methods: Key studies on the safety of anti-TNFα agents in the treatment of adult patients with psoriasis or PsA were identified by a MEDLINE search (last updated 10 November 2011) based on several interrelated queries, with a focus on European registries. Other studies and case reports were included if deemed relevant. Studies concerning other conditions, such as rheumatoid arthritis (RA), were included as appropriate when data in psoriatic disease were unavailable or insufficient. Results: Available data on the safety of anti-TNFα agents such as etanercept in psoriasis and PsA appear reassuring, even if some concerns still exist. Most notably, data suggest a higher incidence of infection and lymphoma amongst patients treated with the anti-TNFα monoclonal antibodies infliximab and adalimumab compared with etanercept. Conclusion: The overall safety profile of monoclonal antibodies in patients with psoriasis, PsA and RA seems less favorable than that of etanercept, particularly in terms of risk of infection and hepatotoxicity.

AB - Context: The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several randomized controlled studies and meta-analyses. However, some concerns on the long-term safety of these drugs still exist, as these studies generally included small patient numbers and were performed in selected patient populations. Objective: This review presents and discusses current evidence on the safety of anti-TNFα agents in patients with psoriasis and PsA, with a focus on European registry studies and case reports of particular importance. Methods: Key studies on the safety of anti-TNFα agents in the treatment of adult patients with psoriasis or PsA were identified by a MEDLINE search (last updated 10 November 2011) based on several interrelated queries, with a focus on European registries. Other studies and case reports were included if deemed relevant. Studies concerning other conditions, such as rheumatoid arthritis (RA), were included as appropriate when data in psoriatic disease were unavailable or insufficient. Results: Available data on the safety of anti-TNFα agents such as etanercept in psoriasis and PsA appear reassuring, even if some concerns still exist. Most notably, data suggest a higher incidence of infection and lymphoma amongst patients treated with the anti-TNFα monoclonal antibodies infliximab and adalimumab compared with etanercept. Conclusion: The overall safety profile of monoclonal antibodies in patients with psoriasis, PsA and RA seems less favorable than that of etanercept, particularly in terms of risk of infection and hepatotoxicity.

KW - Adalimumab

KW - Biological drugs

KW - Etanercept

KW - Golimumab

KW - Infliximab

KW - Psoriasis

KW - Psoriatic arthritis

KW - Registry

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=84863788258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863788258&partnerID=8YFLogxK

U2 - 10.3109/08923973.2011.653646

DO - 10.3109/08923973.2011.653646

M3 - Article

VL - 34

SP - 548

EP - 560

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 4

ER -